Halozyme Therapeutics Inc

Financials

Flusso di cassa derivante dalle attività operative 178.47 M154.22 M99.71 M178.6 M219.03 M 651.56 M Flussi di cassa derivanti dalle attività di investimento 29.48 M-90.42 M84.79 M201.61 M-741.79 M -545.81 M Liquidità derivante dalle attività di finanziamento -246.41 M-3.32 M-298.97 M-22.4 M239.51 M -85.17 M Liquidità libera 175.41 M153.27 M98.15 M175.57 M217.6 M 644.59 M

Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.

HALO

Financials

Halozyme Therapeutics Inc

Notizie

Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock?

TD Cowen conferma rating Buy su Halozyme per crescita royalty

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

La CEO di Halozyme Therapeutics Helen Torley vende azioni per 634.981 dollari

Halozyme concede in licenza la tecnologia Hypercon a Vertex per 15 milioni di dollari

Leerink conferma il rating su Halozyme dopo l’accordo con Vertex

Leaderboard Trimmed, But Cloudflare, Caterpillar Among 5 Stocks To Watch

JNJ: Success In Multiple Myeloma Underpins $25B In Growth By 2030 (NYSE:JNJ)

Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?

Halozyme nomina David Ramsay CFO ad interim

Halozyme names David Ramsay as interim CFO

Halozyme a Citizens Life Sciences: crescita strategica e innovazioni